Emphasys Medical to Present VENT Clinical Trial Data at ATS 2008
Posted on: Monday, 12 May 2008, 18:00 CDT
REDWOOD CITY, Calif., May 12 /PRNewswire/ -- Emphasys Medical Inc., today announced that one-year data from the VENT clinical trial of the company's Zephyr(R) Endobronchial Valve (EBV) will be presented at the International Conference of the American Thoracic Society (ATS) occurring May 16 to 21 in Toronto, Canada.
Sunday, May 18, 9:30-11:00 a.m. (ET), Metro Toronto Convention Centre, Room 801A
In the symposium, "Innovations in Emphysema Treatment: Lung Volume Reduction and Lung Volume Reduction Surgery," Zephyr related presentations include:
-- Frank Sciurba, M.D., University of Pittsburgh Medical Center, the principal investigator of VENT, will present on the Durability of Endobronchial Valve Effect on Lung Function at 6 and 12 Months. -- Jonathan Goldin, M.D., Ph.D., University of California at Los Angeles, the principal investigator of the VENT radiology core lab, will present on Fissure Integrity As a Marker of Collateral Ventilation Across Lung Lobes. -- Jim Egan, M.D., Mater Misericordiae Hospital, Dublin, Ireland, will present on the Treatment of Advanced Emphysema by Endoscopic Volume Reduction. -- John Travaline, M.D., Temple University, will present on the Efficacy of Endobronchial Valves in the Treatment of Persistent Air Leaks. Monday, May 19, 8:30 a.m., Metro Toronto Convention Centre, Room 715A -- Charlie Strange, M.D., Medical University of South Carolina will present on the relation of FEV1/FVC and Fissure Integrity in the VENT Study. Monday, May 19, 3:10 p.m., Metro Toronto Convention Centre, Hall G -- Frank Sciurba, M.D., will present on Bronchoscopic Methods for Palliation of Emphysema. About the Zephyr Endobronchial Valve
The Zephyr EBV is a novel, minimally-invasive device intended to treat emphysema. The Zephyr EBV is designed to isolate diseased, overinflated portions of the lung and cause them to shrink thereby allowing healthier portions of the lung to function more normally.
The Zephyr EBV is CE marked and is commercially available in Europe and other international markets, including Australia, New Zealand, Hong Kong and Singapore. The Zephyr EBV is limited to investigational use in the United States. The company's Premarket Approval Application is currently under review by the U.S. Food and Drug Administration.
About Emphasys Medical
Emphasys Medical (http://www.emphasysmedical.com/) is a medical technology company focused on developing and commercializing therapeutic devices for the treatment of patients with emphysema and other debilitating breathing disorders. Based in Redwood City, California, Emphasys Medical was incubated at The Foundry.
Emphasys Medical Inc.
CONTACT: Greg Bakan of Emphasys Medical, +1-650-364-0400,info@emphasysmedical.com
Web site: http://www.emphasysmedical.com/
Source: PRNewswire
Related Articles
- VIDA Diagnostics and Veran Medical Sign Definitive Agreement for Joint Development of Endobronchial Navigation System
- ULURU Inc. to Present Altrazeal(TM) Clinical Evidence at the American Podiatric Medical Association (APMA) Annual Scientific Meeting in Toronto, Canada
- Veran Medical Enables Breakthrough 4D Navigation to Cancer Lesions at University of Virginia Hospital
- NewCardio Medical and Technology Team Presents Two Abstracts at Heart Rhythm Society Conference
- Rockwell Medical Technologies, Inc. To Present At 2008 Barrington Research Healthcare Conference
- Market Wire to Present at Bulldog Reporter's PR University
- Medical Nutrition USA to Present at Rodman & Renshaw Eighth Annual Healthcare Conference
- Enloe Medical Center Workers to Present COO With 'Scrooge of the Year' Award at Press Conference Today
- NMT Medical Clinical Trial Data Presented at the TCT Symposium
- CAS Medical Systems, Inc. Announces Presentation of Test Data From New Near Infra-Red Spectroscopy Technology
 |
 |
User Comments (0)
RSS Feeds